The invention relates to the field of medicine and can be used in the pharmaceutical industry for producing a drug for treating a disease correlated with macular oedema associated with VEGF-A overexpression. An F(ab)2-fragment of anti-VEGF-A antibody is provided as active substance of the drug for treating a disease correlated with macular oedema caused by VEGF-A overexpression. Moreover, the aforementioned dimer can comprise additional amino acid sequences, which improve the pharmacological properties thereof. The use of the present invention makes it possible to improve the ease of use of the anti-VEGF-A-therapy for macular oedema.
展开▼
